We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo Files for COPD Drug; FluLaval Approved for Infants
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) and partner Innoviva, Inc. (INVA - Free Report) announced filing of a regulatory submission in the U.S. for a once-daily, closed triple combination therapy (fluticasone furoate, FF/umeclidinium, UMEC/vilanterol, VI) for chronic obstructive pulmonary disease (COPD). Encouragingly, the company submitted a regulatory application for the therapy around 18 months earlier than its expectations.
While fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2-adrenergic agonist (LABA). The combination medicine will be delivered once daily in the Ellipta dry powder inhaler. Typically, th ICS/LAMA/LABA combinations for advanced COPD are delivered via two or more inhalers with a potentially differing dose regime. However, Glaxo’s triple therapy combination offers a daily treatment in a single Ellipta inhaler.
The filing was based on data from the closed triple combination therapy development program, as well as results of the phase III FULFIL study on FF, UMEC and VI either alone or in combination. The study revealed superiority of the closed triple combination over Symbicort Turbohaler in improving lung function and health-related quality of life in COPD patients.
Glaxo intends to submit a regulatory filing in the EU in the coming weeks, which will likely be followed by submissions in other countries beginning in 2017.
In a separate press release, Glaxo announced that it has received approval from the FDA’s Center for Biologics Evaluation and Research for a label expansion of its vaccine FluLaval Quadrivalent (Influenza Vaccine) for use in children aged 6 months and older. Prior to this, the vaccine was approved only for the treatment of patients aged 3 years and above as active immunization against influenza.
The supplemental Biologics License Application (sBLA) was based on a pivotal phase III study and three supportive clinical studies conducted in children aged 6 months to 35 months of age.
Currently approved quadrivalent influenza vaccines include AstraZeneca’s (AZN - Free Report) intranasalinfluenza vaccine FluMist Quadrivalent and Sanofi’s (SNY - Free Report) quadrivalent formulation of Fluzone.
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 20,000 children under the age of 5 years are hospitalized due to influenza complications. This means that an approval in this expanded indication will allow it to launch the first quadrivalent (four-strain) flu vaccine in the US.
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Glaxo Files for COPD Drug; FluLaval Approved for Infants
GlaxoSmithKline plc (GSK - Free Report) and partner Innoviva, Inc. (INVA - Free Report) announced filing of a regulatory submission in the U.S. for a once-daily, closed triple combination therapy (fluticasone furoate, FF/umeclidinium, UMEC/vilanterol, VI) for chronic obstructive pulmonary disease (COPD). Encouragingly, the company submitted a regulatory application for the therapy around 18 months earlier than its expectations.
While fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2-adrenergic agonist (LABA). The combination medicine will be delivered once daily in the Ellipta dry powder inhaler. Typically, th ICS/LAMA/LABA combinations for advanced COPD are delivered via two or more inhalers with a potentially differing dose regime. However, Glaxo’s triple therapy combination offers a daily treatment in a single Ellipta inhaler.
The filing was based on data from the closed triple combination therapy development program, as well as results of the phase III FULFIL study on FF, UMEC and VI either alone or in combination. The study revealed superiority of the closed triple combination over Symbicort Turbohaler in improving lung function and health-related quality of life in COPD patients.
Glaxo intends to submit a regulatory filing in the EU in the coming weeks, which will likely be followed by submissions in other countries beginning in 2017.
In a separate press release, Glaxo announced that it has received approval from the FDA’s Center for Biologics Evaluation and Research for a label expansion of its vaccine FluLaval Quadrivalent (Influenza Vaccine) for use in children aged 6 months and older. Prior to this, the vaccine was approved only for the treatment of patients aged 3 years and above as active immunization against influenza.
The supplemental Biologics License Application (sBLA) was based on a pivotal phase III study and three supportive clinical studies conducted in children aged 6 months to 35 months of age.
Currently approved quadrivalent influenza vaccines include AstraZeneca’s (AZN - Free Report) intranasalinfluenza vaccine FluMist Quadrivalent and Sanofi’s (SNY - Free Report) quadrivalent formulation of Fluzone.
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 20,000 children under the age of 5 years are hospitalized due to influenza complications. This means that an approval in this expanded indication will allow it to launch the first quadrivalent (four-strain) flu vaccine in the US.
GLAXOSMITHKLINE Price
GLAXOSMITHKLINE Price | GLAXOSMITHKLINE Quote
Zacks Rank
Glaxo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>